Total Funding
77
76
Total FundingPost-IPO Debt raised
Growth Score
-15 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
27603
Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases.
Donato Spota: CFOPast Role: Basilea Pharmaceutica, Chief Financial Officer
Max Sakajja: Vice President and General Manager of Europe and InternationalPast Role: Swedish Orphan Biovitrum, Mergers & Acquisitions Director
About the Company
Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases. They concentrate on creating novel, life-saving and life-changing treatments that can meet the critical, unmet medical needs of individuals with uncommon immunological disorders. To target pathogenic or
disease-causing antibodies, they developed its proprietary antibody-cleaving enzyme technology platform. The company's diverse therapeutic pipeline has the potential to address significant unmet medical needs in transplantation, autoimmune diseases, gene therapy, and oncology indications.
